Literature DB >> 17233800

The incidence of high-grade prostatic intraepithelial neoplasia and atypical glands suspicious for carcinoma on first-time saturation needle biopsy, and the subsequent risk of cancer.

Lynn Schoenfield1, J Stephen Jones, Craig D Zippe, Alwyn M Reuther, Eric Klein, Ming Zhou, Cristina Magi-Galluzzi.   

Abstract

OBJECTIVE: To investigate the detection rate and extent of high-grade prostatic intraepithelial neoplasia (HGPIN) and atypical glands (AG) suspicious for prostate cancer, and the cancer risk in subsequent biopsies, diagnosed by a first 24-core saturation biopsy, as although the optimum extent of biopsy is controversial there is a trend to increase the number of cores taken, and apart from detecting prostate cancer, identifying HGPIN and AG is associated with a greater risk of finding cancer in subsequent biopsies, thus warranting a closer follow-up. PATIENTS AND METHODS: The study included 100 men with consecutive first-time saturation biopsies; the indications for biopsy were an abnormal digital rectal examination and/or a serum prostate-specific antigen (PSA) level of >2.5 ng/mL. Each biopsy specimen was reviewed retrospectively by two pathologists to confirm the histological diagnosis. The number and percentage of cores positive for HGPIN, bilateral involvement and multifocality (HGPIN involving two or more cores) were recorded in each case. The presence of AG and cancer was also recorded. An extended (10-12 cores) repeat biopsy was available in 23 patients.
RESULTS: The median (range) age and PSA level of the patients was 63 (41-80) years and 4.9 (1.5-67.0) ng/mL, respectively. Of the 100 patients, 34% had normal findings (benign prostatic tissue, BPT), 39% had cancer, 26% had HGPIN and cancer, 22% had HGPIN alone, and 5% had AG. Repeat biopsies were available in nine of the 22 (41%) patients with HGPIN, four of five with AG, and 10 of the 34 (29%) with BPT. The median (range) interval between the first and second biopsy was 13 (4-36) months. Prostate cancer was detected at the second biopsy in a third of patients with isolated HGPIN on the first biopsy, and one of the four with AG. None of the patients with BPT had cancer on re-biopsy. The cancer detection rate was significantly greater in patients with multifocal than in those with unifocal HGPIN (80% vs none, P = 0.010). The median number of cores and percentage of tissue involved by HGPIN was 3.5 (2-5) and 1.0 (0.5-1.2)%, respectively, in patients with cancer detected in repeat biopsies, compared to 1.0 (1-3) and 0.2 (0.2-0.6)% in patients without cancer on repeat biopsy (P = 0.023 and 0.015, respectively).
CONCLUSION: Identifying multifocal HGPIN on first saturation biopsy is associated with an overall cancer detection rate of 80% on repeat 10-12-core biopsy. Although there were few patients, the detection of multifocal HGPIN warrants additional searches for concurrent invasive carcinoma by repeated biopsy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17233800     DOI: 10.1111/j.1464-410X.2006.06728.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  20 in total

1.  Is repeat biopsy for isolated high-grade prostatic intraepithelial neoplasia necessary?

Authors:  Arnold I Chin; Dhiren S Dave; Jacob Rajfer
Journal:  Rev Urol       Date:  2007

Review 2.  Strategies for repeat prostate biopsies.

Authors:  Martha K Terris
Journal:  Curr Urol Rep       Date:  2009-05       Impact factor: 3.092

3.  Heterogeneous clinicopathological features of intraductal carcinoma of the prostate: a comparison between "precursor-like" and "regular type" lesions.

Authors:  Kosuke Miyai; Mukul K Divatia; Steven S Shen; Brian J Miles; Alberto G Ayala; Jae Y Ro
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15

Review 4.  Management of rising prostate-specific antigen after a negative biopsy.

Authors:  David A Levy; J Stephen Jones
Journal:  Curr Urol Rep       Date:  2011-06       Impact factor: 3.092

Review 5.  Managing high-grade prostatic intraepithelial neoplasia (HGPIN) and atypical glands on prostate biopsy.

Authors:  Jeffrey J Tosoian; Ridwan Alam; Mark W Ball; H Ballentine Carter; Jonathan I Epstein
Journal:  Nat Rev Urol       Date:  2017-08-31       Impact factor: 14.432

6.  Challenges and potential solutions to meeting accrual goals in a Phase II chemoprevention trial for prostate cancer.

Authors:  Nagi Kumar; Theresa Crocker; Tiffany Smith; Julio Pow-Sang; Philippe E Spiess; Kathleen Egan; Gwen Quinn; Michael Schell; Said Sebti; Aslam Kazi; Tian Chuang; Raoul Salup; Mohamed Helal; Gregory Zagaja; Edouard Trabulsi; Jerry McLarty; Tajammul Fazili; Christopher R Williams; Fred Schreiber; Joel Slaton; J Kyle Anderson
Journal:  Contemp Clin Trials       Date:  2011-11-11       Impact factor: 2.226

Review 7.  Precursor lesions to prostatic adenocarcinoma.

Authors:  Jonathan I Epstein
Journal:  Virchows Arch       Date:  2008-12-02       Impact factor: 4.064

8.  Deregulation of FoxO3a accelerates prostate cancer progression in TRAMP mice.

Authors:  Sanjeev Shukla; Natarajan Bhaskaran; Gregory T Maclennan; Sanjay Gupta
Journal:  Prostate       Date:  2013-06-13       Impact factor: 4.104

9.  Risk of prostate cancer after detection of isolated high-grade prostatic intraepithelial neoplasia (HGPIN) on extended core needle biopsy: a UK hospital experience.

Authors:  Paras B Singh; Caroline M Nicholson; Narasimhan Ragavan; Rosemary A Blades; Francis L Martin; Shyam S Matanhelia
Journal:  BMC Urol       Date:  2009-05-27       Impact factor: 2.264

10.  Development and validation of risk score for predicting positive repeat prostate biopsy in patients with a previous negative biopsy in a UK population.

Authors:  Mark A Rochester; Nora Pashayan; Fiona Matthews; Andrew Doble; John McLoughlin
Journal:  BMC Urol       Date:  2009-07-16       Impact factor: 2.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.